Human CellExp™ IL-5, Human Recombinant

(No reviews yet) Write a Review
SKU:
26-P1486
Availability:
Usually Shipped in 5 Working Days
Storage Temperature:
-20ºC
Shipping Conditions:
Gel Pack
Shelf Life:
12 months
€241.00 - €647.00
Frequently bought together:

Description

Biomolecule/Target: N/A

Synonyms: Interleukin-5, IL-5, B-cell differentiation factor I, Eosinophil differentiation factor, T-cell replacing factor, TRF

Alternates names: Interleukin-5, IL-5, B-cell differentiation factor I, Eosinophil differentiation factor, T-cell replacing factor, TRF

Taglines: Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 3567

NCBI Gene Symbol: IL5

Gene Source: Human

Accession #: P05113

Recombinant: False

Source: HEK 293 cells

Purity by SDS-PAGE #: >95%

Assay: N/A

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): ED50 is typically < 1 ng/mL. The specific activity was determined by the dose dependent stimulation of the proliferation of Human TF-1 cells using BioVision’s Quick Cell Proliferation colorimetric Assay Kit Plus (Cat. No. K302).

Biological activity: N/A

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 14 kDa with a 6×His tag at the N-terminus

Concentration: N/A

Appearance: Lyophilized powder

Physical form description: Lyophilized

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS (pH 7.4). Do not vortex.

Background Information: Interleukin-5 (IL-5) is identified by its ability to support the growth and terminal differentiation of mouse B cells to immunoglobulin secreting cells. IL-5 also exerts pleiotropic activities on various target cells including eosinophils and basophils via receptors of IL-5-specific α and common β-subunit. IL-5’s stimulation of eosinophil has been implicated in the pathogenesis of allergic inflammatory diseases, such as asthma. Targeting the interleukin-5 pathway offers benefit to patients with severe asthma. Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Amino acid sequence: Ile 20 – Ser 134

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans

View AllClose